Antibe Therapeutics

Antibe Therapeutics is a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.

Antibe Therapeutics Inc.
Company typePublicly traded corporation
Traded as
TSX: ATE
IndustryPharmaceuticals
Founded1 January 2010 
Headquarters
Toronto
,
Canada
Key people
Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer
Websitewww.antibethera.com

On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.

On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.